Philadelphia University + Thomas Jefferson University

Dicker, Adam

< Back


Adam P. Dicker, MD, PhD, FASTRO

Adam P. Dicker, MD, PhD, FASTRO

Contact Dr. Dicker

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6700
(215) 503-0013 fax

Research & Clinical Interest

My mission, “Empowering patients through translational cancer research."

As Chair & Professor of Radiation Oncology, Pharmacology and Experimental Therapeutics at Thomas Jefferson University, I coordinate an interdisciplinary team of oncologists, physicists and scientists focused on multidisciplinary effort to define fundamental mechanisms and targets for combined modality radiation treatment and efficiently translate them to effective innovations in treating cancer patients.

Our group defined for prostate brachytherapy the influence of edema on dosimetric parameters critical for quality metrics, with more recent research correlating radiotherapy protocol deviations and overall survival (JNCI, 2012).  In 2013 I was appointed to the American Society for Radiation Oncology (ASTRO) Radiation Oncology Healthcare Advisory Council for the Radiation Oncology Incident Learning System (PSO) as part of a nationwide effort to improve safety and quality.

Our work funded by the Department of Defense (DoD) and the Prostate Cancer Foundation focuses on the “self-seeding” of prostate cells with metastatic properties back to the site of origin, contributing to disease progression.  I am the PI of a DoD Prostate Synergy Grant, exploring the use of “smart needles” for diagnostic and therapeutic applications.  We have published numerous papers evaluating signal transduction agents with ionizing radiation and published “first in human” developmental therapeutic trials involving novel signal transduction agents and radiation therapy.

I serve as the co-Chair-Translational Science Committee for the NCI cooperative group, NRG Oncology recently awarded a U10 for an Integrated Translational Genoproteomics Center at Washington University.  The long-term objective is to enable delivery of deep tumor ‘omic analysis results to cooperative group investigators for clinical trial screening, eligibility and pharmacodynamic studies of drug action to provide maximal impact in translational medicine.  I have approval authority for the translational research across all solid tumors sites with a particular emphasis on predictive biomarkers, preclinical research, and molecular signatures.  Through a team effort, I coordinated the creation of a NCI–RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers (JNCI, 2013).  I serve on the Clinical, Translational, and Basic Science Advisory Committee of ASTRO and am past Chair of the Radiation and Cancer Biology Committee.  In 2014, I was selected as a Fellow of ASTRO designation (FASTRO), for contributions to the field of radiation oncology in the areas of research, education, patient care, service, and leadership.

I represent the NRG Oncology on the National Cancer Institute’s Investigational Drug Steering Committee of CTEP and am a consultant on Cancer to the European Commission, the National Cancer Institute of Canada and the Italian Association of Cancer Research.  I was recently appointed as a member of the Integration Panel for the Prostate Cancer Research Program of the DoD.  I have supervised over 40 Residents who worked with me on my clinical service.  Many of my trainees are early and mid-career clinician researchers and clinician-scientists in academic medicine here and abroad.

I have experience in clinical care, quality assurance & patient safety, prostate cancer, clinical trials, facilitating RTOG/NRG Oncology investigator research, drug development, entrepreneurship, preclinical model systems, biomarker analysis, and mentorship.

PubMed - A link to Dr. Dicker's publications


Most Recent Peer-Reviewed Publications

  1. Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle
  2. Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy
  3. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology
  4. Blockade of Tumor-Expressed PD-1 promotes lung cancer growth
  5. PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes
  6. Utilizing 10-Year Results From the American Board of Radiology Clinical Examination to Identify Areas for Programmatic Improvement
  7. Common error pathways seen in the RO-ILS data that demonstrate opportunities for improving treatment safety
  8. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer
  9. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study
  10. Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704
  11. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
  12. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
  13. Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities
  14. Phase i Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib with Concurrent Radiotherapy for Advanced Head and Neck Cancer
  15. Ensuring sample quality for blood biomarker studies in clinical trials: A multicenter international study for plasma and serum sample preparation
  16. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
  17. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer the NRG oncology rtog 0436 phase 3 randomized clinical trial
  18. Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non–Small Cell Lung Cancer: NRG Oncology RTOG 0839
  19. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
  20. Increasing faculty participation in resident education and providing cost-effective self-assessment module credit to faculty through resident-generated didactics